{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"PRO1184"},{"type":"Synonym","name":"anti-FRa/exatecan ADC PRO1184"},{"type":"CodeName","name":"PRO 1184"},{"type":"CodeName","name":"PRO-1184"},{"type":"Synonym","name":"ADC PRO1184"}],"definition":{"html":"An antibody-drug conjugate (ADC) composed of a human monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) conjugated, via a cleavable hydrophilic linker, to the camptothecin analog and topoisomerase 1 inhibitor exatecan, with potential antineoplastic activity. Upon administration of anti-FRalpha/exatecan ADC PRO1184, the antibody moiety targets and binds to FRa expressed on tumor cells. Upon binding, cellular uptake and linker cleavage, exatecan is released. Exatecan inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and generating DNA single- and double-strand breaks, and leading to cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of FRa-expressing tumor cells. FRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers while its expression is limited in normal tissues.","text":"An antibody-drug conjugate (ADC) composed of a human monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) conjugated, via a cleavable hydrophilic linker, to the camptothecin analog and topoisomerase 1 inhibitor exatecan, with potential antineoplastic activity. Upon administration of anti-FRalpha/exatecan ADC PRO1184, the antibody moiety targets and binds to FRa expressed on tumor cells. Upon binding, cellular uptake and linker cleavage, exatecan is released. Exatecan inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and generating DNA single- and double-strand breaks, and leading to cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of FRa-expressing tumor cells. FRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers while its expression is limited in normal tissues."},"drugInfoSummaryLink":null,"nciConceptId":"C192818","nciConceptName":"Anti-FRalpha/Exatecan ADC PRO1184","termId":811560,"name":"anti-FRalpha/exatecan ADC PRO1184","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"anti-fralpha-exatecan-adc-pro1184"}],"links":null}